LCTX Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Lineage Cell Therapeutics Inc

Watchlist Manager

Watchlist

Price: 355.1 ILS 0.71% Market Closed

Market Cap: ₪280.8m

L	Lineage Cell Therapeutics Inc TASE:LCTX	US
	Societe Generale SA PAR:GLE	FR
	Reliance Steel & Aluminum Co NYSE:RS	US

Profitability Summary

Lineage Cell Therapeutics Inc's profitability score is 15/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

99%

Strong 3Y Average Gross Margin

95%

Gross Margin is Increasing

94% > 99%

Negative Operating Margin

-150%

Negative 3Y Average Operating Margin

-249%

Operating Margin is Increasing

-192% > -150%

Negative Net Margin

-436%

Negative 3Y Average Net Margin

-312%

Declining Net Margin

-199% > -436%

Negative Free Cash Flow Margin

-134%

Negative 3Y Average Free Cash Flow Margin

-267%

Free Cash Flow Margin is Increasing

-275% > -134%

Negative ROE

-103%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-37%

ROIC is Increasing

-35% > -34%

View All

Hide

Collapse

15 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.